CN115279401A - 聚合物纳米颗粒作为疫苗佐剂 - Google Patents

聚合物纳米颗粒作为疫苗佐剂 Download PDF

Info

Publication number
CN115279401A
CN115279401A CN202080097299.0A CN202080097299A CN115279401A CN 115279401 A CN115279401 A CN 115279401A CN 202080097299 A CN202080097299 A CN 202080097299A CN 115279401 A CN115279401 A CN 115279401A
Authority
CN
China
Prior art keywords
nanoparticles
composition
response
particles
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080097299.0A
Other languages
English (en)
Chinese (zh)
Inventor
E·拉韦尔
N·穆诺茨-沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Publication of CN115279401A publication Critical patent/CN115279401A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202080097299.0A 2019-12-20 2020-12-21 聚合物纳米颗粒作为疫苗佐剂 Pending CN115279401A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1918963.8A GB201918963D0 (en) 2019-12-20 2019-12-20 Polymeric nanoparticles as vaccine adjuvants
GB1918963.8 2019-12-20
PCT/EP2020/087456 WO2021123430A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants

Publications (1)

Publication Number Publication Date
CN115279401A true CN115279401A (zh) 2022-11-01

Family

ID=69322661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080097299.0A Pending CN115279401A (zh) 2019-12-20 2020-12-21 聚合物纳米颗粒作为疫苗佐剂

Country Status (8)

Country Link
US (1) US20230218752A1 (https=)
EP (1) EP4076519A1 (https=)
JP (2) JP2023507497A (https=)
CN (1) CN115279401A (https=)
AU (1) AU2020407306A1 (https=)
CA (1) CA3162350A1 (https=)
GB (1) GB201918963D0 (https=)
WO (1) WO2021123430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657210B (zh) * 2022-03-03 2023-08-11 中山大学孙逸仙纪念医院 一种基于负载gsdmd蛋白n端肽段的纳米材料及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437491A (zh) * 2006-02-21 2009-05-20 洛桑聚合联合学院 用于免疫疗法的纳米颗粒
CN102202653A (zh) * 2008-08-29 2011-09-28 洛桑聚合联合学院 用于免疫疗法的纳米颗粒
CN104338126A (zh) * 2013-08-08 2015-02-11 中国科学院过程工程研究所 一种具有治疗或预防hpv病毒的疫苗组合物及其应用
WO2017151922A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
WO2019023622A1 (en) * 2017-07-27 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
JP4526708B2 (ja) 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤
JP6008345B2 (ja) 2009-02-27 2016-10-19 東レ株式会社 免疫原性組成物
US9572894B2 (en) 2010-10-18 2017-02-21 The University Of Iowa Research Foundation Biodegradable particulate formulations
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437491A (zh) * 2006-02-21 2009-05-20 洛桑聚合联合学院 用于免疫疗法的纳米颗粒
CN102202653A (zh) * 2008-08-29 2011-09-28 洛桑聚合联合学院 用于免疫疗法的纳米颗粒
CN104338126A (zh) * 2013-08-08 2015-02-11 中国科学院过程工程研究所 一种具有治疗或预防hpv病毒的疫苗组合物及其应用
WO2017151922A1 (en) * 2016-03-02 2017-09-08 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
WO2019023622A1 (en) * 2017-07-27 2019-01-31 The Board Of Trustees Of The Leland Stanford Junior University POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENXI LI 等: "Synthetic Polymeric Mixed Micelles Targeting Lymph Nodes Trigger Enhanced Cellular and Humoral Immune Responses", 《ACS APPL MATER INTERFACES》, vol. 10, no. 3, 10 January 2018 (2018-01-10), XP055669530, DOI: 10.1021/acsami.7b14004 *
THEODORA FIFIS等: "Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors", 《J IMMUNOL》, vol. 173, no. 5, 1 September 2004 (2004-09-01), pages 3148 - 3149 *
宋永焕等: "壳聚糖纳米颗粒免疫刺激作用的初步研究", 《浙江医学》, vol. 30, no. 11, 20 November 2008 (2008-11-20), pages 1208 - 1210 *
杨蕴琦、闻晓波: "纳米颗粒佐剂的应用现状及发展前景", 《现代畜牧兽医》, no. 5, 15 May 2017 (2017-05-15), pages 50 - 51 *

Also Published As

Publication number Publication date
JP2023507497A (ja) 2023-02-22
JP2026015426A (ja) 2026-01-29
CA3162350A1 (en) 2021-06-24
EP4076519A1 (en) 2022-10-26
GB201918963D0 (en) 2020-02-05
AU2020407306A1 (en) 2022-07-07
US20230218752A1 (en) 2023-07-13
WO2021123430A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
Zhao et al. Vaccine adjuvants: mechanisms and platforms
Feng et al. Immunomodulatory nanosystems
Foged Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems
Zhao et al. The application of self-assembled nanostructures in peptide-based subunit vaccine development
Sun et al. The quest for nanoparticle-powered vaccines in cancer immunotherapy
Wang et al. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain
Demento et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
JP6434995B2 (ja) 界面活性剤を含まない水中油エマルジョン及びその用途
van Riet et al. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design
Jin et al. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses
Sokolova et al. The potential of nanoparticles for the immunization against viral infections
Ebrahimian et al. Co-delivery of dual toll-like receptor agonists and antigen in poly (lactic-co-glycolic) acid/polyethylenimine cationic hybrid nanoparticles promote efficient in vivo immune responses
CN113440605B (zh) 一种全细胞组分的输送系统及其应用
Hou et al. Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses
Eby et al. Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization
CN108324938B (zh) 一种颗粒型佐剂及其制备方法和应用
Simón-Vázquez et al. Polymeric nanostructure vaccines: applications and challenges
Kaur et al. Combined delivery of TLR2 and TLR7 agonists by Nanostructured lipid carriers induces potent vaccine adjuvant activity in mice
JP2026015426A (ja) ワクチンアジュバントとしてのポリマーナノ粒子
WO2023040127A1 (zh) 基于全细胞组分的癌症疫苗系统在制备交叉预防或治疗异种癌症药物中的应用
Xiang et al. Nanoparticles, immunomodulation and vaccine delivery
Foyez et al. Nanotechnology in vaccine development and constraints
Hartmeier et al. Immune cells activating biotin-decorated PLGA protein carrier
Adams et al. Enhancing the immune response through next generation polymeric vaccine adjuvants
Ebrahim et al. Nano-Vaccines: Pioneering the Future of Immunization

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination